The GLP is committed to full transparency. Download and review our 2019 Annual Report

Genetic test could spare thousands from chemotherapy

| | September 26, 2013
This article or excerpt is included in the GLP’s daily curated selection of ideologically diverse news, opinion and analysis of biotechnology innovation.

Doctors could use the test to determine whether or not a patient’s cancer is likely to spread to other parts of the body, which prompts the need for toxic chemotherapy treatment.

An estimated 9,700 patients with certain types of early stage breast cancer would to be offered the test each year, and in a third of cases treatment regimes are likely to be altered as a result.

For those whose outlook is good, this could mean they are spared gruelling rounds of chemotherapy which result in sideeffects including nausea, vomiting, insomnia, hair loss and fatigue.

Read the full, original story here: Genetic test could spare thousands from chemotherapy

News on human & agricultural genetics and biotechnology delivered to your inbox.
Optional. Mail on special occasions.

Send this to a friend